Drug Profile
Research programme: small molecule therapeutics - PharmaEssentia
Latest Information Update: 29 Aug 2023
Price :
$50
*
At a glance
- Originator PharmaEssentia Corporation
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Beta-thalassaemia; Sickle cell anaemia
Most Recent Events
- 29 Aug 2023 Discontinued - Preclinical for Beta-thalassaemia in Taiwan (unspecified route)
- 29 Aug 2023 Discontinued - Preclinical for Sickle cell anaemia in Taiwan (unspecified route)
- 28 Jan 2019 No recent reports of development identified for preclinical development in Beta-thalassaemia in Taiwan